AKRO vs HRMY โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
HRMY Captures Institutional Edge (3โ1 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Harmony Biosciences Holdings, Inc. Common Stock (HRMY) driven by superior Valuation, Growth & Margin, Options & Structure while AKRO counters with relative strength in Momentum & Technical. Fundamentally, AKRO trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus HRMY at 5.4x Forward P/E and 22.2% operating margin (+12.3% YoY). In options structure, AKRO sits in UNCLASSIFIED (30th %ile IV; Dealer Gamma Walls on Pro) against HRMY sits in CONSOLIDATION (11th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | AKRO | HRMY | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $4.5B | $1.9B | Larger Scale | AKRO |
| Trailing P/E Ratio Valuation | N/M | 10.9x | Lower Multiple | HRMY |
| Forward P/E Ratio Valuation | N/M | 5.4x | Lower Multiple | HRMY |
| Revenue Growth (YoY) Growth | +0.0% | +12.3% | Higher Growth | HRMY |
| Operating Margin (TTM) Profitability | 0.0% | 22.2% | Higher Margin | HRMY |
| Net Profit Margin Profitability | 0.0% | 18.1% | Higher Margin | HRMY |
| Return on Equity (ROE) Capital Efficiency | -34.5% | 18.7% | Higher ROE | HRMY |
| 52-Week Range Position Momentum | 90% ($21โ$58) | 38% ($26โ$43) | Stronger Trend | AKRO |
| Beta / 30D Volatility Risk Regime | 0.90ฮฒ ยท 2% Vol | 0.55ฮฒ ยท 38% Vol | Lower Realized Risk | AKRO |
| Unified Institutional Score Composite Signal | 60.0 / 100 (BUY) | 67.1 / 100 (BUY) | Higher Composite | HRMY |